ClinicalTrials.gg
Drug

Abiraterone Acetate/Niraparib clinical trials

studies test it
3
open now
0
in phase 3
0
first study started
2024

How each study uses Abiraterone Acetate/Niraparib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
11 Aug 2023 · AKEEGA · NDA 216793 (FDA, Drugs@FDA)
European Union
19 Apr 2023 · Akeega · EMEA/H/C/005932 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

niraparib/abiraterone acetate
2
Akeega
2
Abiraterone Acetate/Niraparib
1

Development codes

CJNJ-67652000
1

Studies by the year they started

3 studies that test it; most in 2024 (2)

Studies that test Abiraterone Acetate/Niraparib, by start year
YearStudies
20242
20251

By phase

A phase 1/2 study counts in both.

Phase 2
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 0 · Other 3

University of Maryland, Baltimore (1) · Mayo Clinic (1) · Qian Qin (1)

Often tested with

Tested in the same studies.

Niraparib (3) · Prednisone (2)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses Abiraterone Acetate/Niraparib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 1 — Abiraterone Acetate/Niraparib is usual care or a partner of the new treatment